<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(11)</volume><submitter>Menten-Dedoyart C</submitter><pubmed_abstract>SV2A is a glycoprotein present in the membranes of most synaptic vesicles. Although it has been highly conserved throughout evolution, its physiological role remains largely unknown. Nevertheless, Levetiracetam, a very effective anti-epileptic drug, has been recently demonstrated to bind to SV2A. At present, our understanding of the normal function of SV2A and its possible involvement in diseases like epilepsy is limited. With this study, we sought to develop a relevant model enabling analysis of SV2A's role in the occurrence or progression of epilepsy. For this purpose, we generated a floxed SV2A mouse model with conditional alleles carrying LoxP sites around exon 3 by means of a gene-targeting strategy. The SV2A lox/lox mouse line is indistinguishable from wild-type mice. When the recomb</pubmed_abstract><journal>PloS one</journal><pagination>e0166525</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5115750</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.</pubmed_title><pmcid>PMC5115750</pmcid><pubmed_authors>Bartholome O</pubmed_authors><pubmed_authors>Serrano Navacerrada ME</pubmed_authors><pubmed_authors>Rogister B</pubmed_authors><pubmed_authors>Menten-Dedoyart C</pubmed_authors><pubmed_authors>Sanchez Gil J</pubmed_authors><pubmed_authors>Neirinckx V</pubmed_authors><pubmed_authors>Becker G</pubmed_authors><pubmed_authors>Plenevaux A</pubmed_authors><pubmed_authors>Wislet S</pubmed_authors><pubmed_authors>Van den Ackerveken P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.</name><description>SV2A is a glycoprotein present in the membranes of most synaptic vesicles. Although it has been highly conserved throughout evolution, its physiological role remains largely unknown. Nevertheless, Levetiracetam, a very effective anti-epileptic drug, has been recently demonstrated to bind to SV2A. At present, our understanding of the normal function of SV2A and its possible involvement in diseases like epilepsy is limited. With this study, we sought to develop a relevant model enabling analysis of SV2A's role in the occurrence or progression of epilepsy. For this purpose, we generated a floxed SV2A mouse model with conditional alleles carrying LoxP sites around exon 3 by means of a gene-targeting strategy. The SV2A lox/lox mouse line is indistinguishable from wild-type mice. When the recomb</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016</publication><modification>2026-04-07T17:39:26.725Z</modification><creation>2019-03-26T22:51:11Z</creation></dates><accession>S-EPMC5115750</accession><cross_references><pubmed>27861538</pubmed><doi>10.1371/journal.pone.0166525</doi></cross_references></HashMap>